NAP1L6P
Putative nucleosome assembly protein 1-like 6
Also known as: NP1L6_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for NAP1L6P in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
107 residues, UniProt reviewed canonical sequence.
>A6NFF2|NAP1L6P
1 MMEGLGEHST AGEMGPLLGA VAATASPQSL MEYSSDADFI ESLPLVVKYR VYTLKKLQAK
61 CAVLEAKYLR EFHSVERKFA TIYGPLLEKR RQITNALYEP TKEECERLocalizationUniProt · AlphaFold · HPA
Whether an antibody against NAP1L6P can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.56
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads NAP1L6P as an antibody target. Whether an autoantibody or antibody against NAP1L6P could matter depends on whether native NAP1L6P is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
NAP1L6P is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label NAP1L6P as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...